Navigation Links
Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention

Study results from two research papers have shown that use of the drug Ospemifene in combination with other anti-estrogens for vaginal atrophy reduces the incidence of breast cancer. // The study has been proved in mouse model and researchers are planning for a clinical trial.

DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development. Results show that the mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer and the study result is to be published in the Journal of Steroid Biochemistry and Molecular Biology.

The second study in which the first study author DeGregorio is also a co-author was led by Jeffrey P. Gregg, Associate professor of pathology and laboratory medicine at UC Davis, where they reported that Tamoxifen and Ospemifene both inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ in mouse model.

Ospemifene is a Selective Estrogen Receptor Modulator (SERM), and is an effective anti-estrogen like tamoxifen and raloxifen which is used in the prevention and treatment of breast cancer which binds to estrogens. Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

The advantage of Ospemifene over tamoxifen and raloxifen is due to its reduced side effects as raloxifen can cause hot flashes, insomnia and blood clots. Tamoxifen can cause endometrial cancer in patients undergoing tamoxifen therapy for breast cancer. But ospemifene have a unique estrogen-l ike effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes.
'"/>




Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Increased Risk Of HIV Transmission Following Vaginal Washing
5. Risk Of AIDS Rises With Vaginal Washes
6. Vaginal massage during pregnancy avoids Episiotomy procedure
7. Vaginal Gel That Protects Against HIV To Hit The Markets By 2010
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ‘C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight ... online modeling resource for fluorescence microscopists and optical system designers, enabling The Right ... years spanning the globe, SearchLight has become a tremendously popular tool for the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation ... A Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied ... immediately to IRR programs, the report highlights proven behavioral economics approaches and the ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three new ... first new location will open at the corner of 27th and Randolph in Lincoln, ... this fall. And the third location is in the process of being identified. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology: